---
title: "Hengrui Pharma falls 5% to record low"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306200615.md"
description: "Hengrui Pharma fell 5.08% to HK$43.00. Down 17.59% over ten sessions and down 39.43% YTD."
datetime: "2026-11-20T07:50:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306200615.md)
  - [en](https://longbridge.com/en/news/306200615.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306200615.md)
generator: "portal-rs"
---

# Hengrui Pharma falls 5% to record low

Hengrui Pharma (1276.HK) fell more than **5%** in Hong Kong trading to a record low of **HK$43.00**.

The stock is down 17.59% over the past ten sessions and down 39.43% year to date. It sits 46.73% below its 52-week high of HK$80.72.

The Hang Seng Index is down 5.32% over the past five sessions and down 12.68% year to date.

The pharmaceuticals industry index fell 4.2% over the same period, in line with the stock's move.

The company's CAR-T cancer drug Beinuoda will be included in China's basic medical insurance starting Jan. 1, 2027, with the reimbursement standard cut to 288,600 yuan from 1.29 million yuan, making it the first therapy of its kind covered by the national program.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [Hengrui Announces Drug Inclusions in China’s 2026 NRDL](https://longbridge.com/en/news/305570916.md)
- [Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals](https://longbridge.com/en/news/303205414.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**